[Event Report] The First HGPI Dementia Policy Project Roundtable Discussion on “Establishing a Multi-Stakeholder Public-Private Partnership in the Field of Dementia – Driving Parallel Progress on an Inclusive Society and in R&D” (August 31, 2022)
date : 9/28/2022
Tags: Dementia
![[Event Report] The First HGPI Dementia Policy Project Roundtable Discussion on “Establishing a Multi-Stakeholder Public-Private Partnership in the Field of Dementia – Driving Parallel Progress on an Inclusive Society and in R&D” (August 31, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/d1f548405b0cfbda57b565bb2492b999.jpg)
On August 31, 2022, Health and Global Policy Institute (HGPI) held the first roundtable discussion for an initiative titled, “Establishing a Multi-Stakeholder Public-Private Partnership in the Field of Dementia – Driving Parallel Progress on an Inclusive Society and in R&D.” The meeting was held online and was not open to the public.
HGPI views dementia and all other aging-related issues as health policy issues at the global level and has made continuous efforts in its capacity as a non-profit, independent health policy think tank to advance policies in this area around the world. In particular, HGPI was early to call for all-of-government initiatives for addressing dementia and has issued multiple recommendations to that end. The fruits of these efforts can be seen in the National Framework for Promotion of Dementia Policies formulated in 2019.
However, establishing a Public Private Partnership (PPP) that enables industry, Government, academia, and civil society to collaborate in R&D in the field of dementia and to achieve a dementia-friendly society remains an issue. In other fields such as cancer, there have already been initiatives to advance R&D with active involvement from patient advocacy organizations in clinical trials. The field of dementia has also reached the point where we should establish a platform that enables a broad variety of stakeholders to collaborate on the creation of an inclusive society and to promote R&D.
After a preliminary survey of members from academia was conducted and issues were sorted, this roundtable discussion examined issues and next steps to be taken with three discussion points as themes:
Discussion point 1: Policy issues surrounding R&D and the direction to take moving forward
Discussion point 2: Challenges facing Patient and Public Involvement (PPI) in dementia research
Discussion point 3: Issues surrounding R&D programs
This roundtable was a significant opportunity for multi-stakeholders representing industry, Government, academia, and civil society to meet and exchange opinions on the future of R&D in a manner that surpassed each member’s position and field.
■ Roundtable discussion members (titles omitted; in Japanese syllabary order)
- Haruhiko Akiyama (Director of Clinical Research, Department of Clinical Research, Yokohama Municipal Stroke and Neurospine Center)
- Takeshi Ikeuchi (Professor, Center for Bioresource-based Researches, Brain Research Institute, Niigata University)
- Kenji Ishii (Team Leader, Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology)
- Takeshi Iwatsubo (Professor, Department of Basic Neuroscience, Department of Neurology, Graduate School of Medicine, The University of Tokyo; Director, Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital)
- Hidetaka Ota (Professor and Director, Advanced Research Center for Geriatric and Gerontology, Akita University (ARGG))
- Tomoo Ogawa (Director, Department of Clinical Research and Development, Japan-Asia, Alzheimer’s Disease and Brain Health, Eisai Co., Ltd.)
- Hideaki Katagiri (Medical Fellow and Lead Physician, Neuroscience & Pain, Medicine Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K.)
- Naomi Sakurai (President, Cancer Solutions Co., Ltd.)
- Keisuke Suzuki (Director, Innovation Center for Translational Research, National Center for Geriatrics and Gerontology)
- Morio Suzuki (Representative Director, Alzheimer’s Association Japan (AAJ))
- Taro Semba (Director, Dementia Project Promotion Office, SOMPO Holdings, Inc.)
- Toshihisa Tanaka (Professor, Department of Neuromuscular Pathology, Mie University)
- Taisuke Tomita (Professor, Laboratory of Neuropathology & Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
- Jin Higashijima (Associate Professor, Graduate School of Global and Transdisciplinary Studies, Chiba University)
- Masaaki Hirai (Representative, Mahoroba Club)
Top Research & Recommendations Posts
- [Publication Report] Planetary Health Promotion Project “Issues Facing Planetary Health and the Role of the Health Sector” (May 10, 2023)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Building a Research and Development System Together With People Living with Dementia and Their Families to Drive Parallel Progress in Creating an Inclusive Society and Advancing R&D (April 25, 2023)
- [Public Comment Submission] Opinions Regarding the Proposed “National Action Plan on Antimicrobial Resistance 2023-2027 (Draft)” (March 16, 2023)
- [Recommendations] Recommendations for the G7 Hiroshima Summit in 2023 Necessary Actions for AMR Control, Starting with the Introduction of Pull Incentives (August 29, 2022)
- [Policy Recommendations] Recommendations for the G7 Hiroshima Summit by the C7 Global Health Working Group (April 20, 2023)
- [Policy Recommendations] Requests for the G7 Hiroshima Summit and Related Ministerial Meetings: Promoting Measures for Climate Change and Planetary Health That Keep Pace With the International Community (December 19, 2022)
- [Research Report] The Public Opinion Survey on Mental Health (August 12, 2022)
- [Recommendations] Restructuring Diagnostic Services and Achieving the Necessary Innovation to Promote AMR Control (May 26, 2023)
Featured Posts
-
2023-05-12
[Event Report] Recommendations to Prime Minister Fumio Kishida on the issue of antimicrobial resistance (AMR) in the G7 Hiroshima Summit Leaders’ Declaration (April 28, 2023)
-
2023-05-15
[Event Report] (Live Broadcasting) A Dementia Symposium Commemorating the G7 Health Ministers’ Meeting in Nagasaki “Collaboration in the International Community for Advancing Dementia Measures in a New Era” (May 14, 2023)
-
2023-05-18
[Event Report] A NAGASAKI Planetary Health Expert Meeting “From COP27 and COP15 to the G7 Hiroshima Summit: New Partnerships for Solving Climate, Environment, Biodiversity and Health Issues” (May 12, 2023)
-
2023-05-19
[RegistrationOpen] Health Policy Academy the 12th Session
-
2023-05-26
[Recommendations] Restructuring Diagnostic Services and Achieving the Necessary Innovation to Promote AMR Control (May 26, 2023)